UiPath (NYSE:PATH) Price Target Raised to $18.00 at Bank of America

UiPath (NYSE:PATH) had its price objective lifted by Bank of America from $16.00 to $18.00 in a report released on Friday morning, Benzinga reports. They currently have a neutral rating on the healthcare company’s stock.

Other analysts have also recently issued reports about the stock. Mizuho lowered their price objective on shares of UiPath from $25.00 to $14.00 and set a neutral rating for the company in a research note on Thursday, May 30th. Canaccord Genuity Group dropped their price target on UiPath from $30.00 to $19.00 and set a buy rating for the company in a research note on Friday, May 31st. BMO Capital Markets lifted their price objective on UiPath from $14.00 to $15.00 and gave the company a market perform rating in a research note on Friday. Wells Fargo & Company cut their price target on shares of UiPath from $15.00 to $14.00 and set an equal weight rating on the stock in a report on Friday, June 21st. Finally, TD Cowen reiterated a hold rating and set a $17.00 price objective (down from $28.00) on shares of UiPath in a research note on Thursday, May 30th. Sixteen equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Hold and an average price target of $17.71.

UiPath Trading Down 6.0 %

NYSE PATH opened at $11.98 on Friday. The business’s 50-day moving average price is $12.20 and its 200 day moving average price is $16.71. UiPath has a twelve month low of $10.37 and a twelve month high of $27.87. The company has a market capitalization of $6.86 billion, a PE ratio of -74.84 and a beta of 0.87.

UiPath (NYSE:PATH) last announced its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. The business had revenue of $316.00 million for the quarter, compared to analyst estimates of $303.69 million. During the same period in the prior year, the firm posted ($0.09) EPS. The company’s revenue was up 10.0% on a year-over-year basis. Equities analysts predict that UiPath will post -0.22 EPS for the current year.

Institutional Trading of UiPath

A number of hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of UiPath in the 4th quarter valued at approximately $165,749,000. Pacer Advisors Inc. acquired a new stake in shares of UiPath during the second quarter worth $69,180,000. Vanguard Group Inc. lifted its position in shares of UiPath by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock worth $911,741,000 after buying an additional 2,133,078 shares during the last quarter. Artisan Partners Limited Partnership acquired a new position in shares of UiPath in the 4th quarter valued at about $48,267,000. Finally, Renaissance Technologies LLC bought a new stake in shares of UiPath during the 2nd quarter valued at about $13,280,000. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.